{"chunk_type":"transcript_chunk","text":"- **ì‹œë‚˜ë¦¬ì˜¤:** ì Šê³  ë§ˆë¥¸ í™˜ì(24ì„¸, BMI 21), ê²½ë¯¸í•œ ê³ í˜ˆë‹¹.\n- **í•¨ì •:** 1í˜•ì²˜ëŸ¼ ë³´ì´ì§€ë§Œ(ì Šê³  ë§ˆë¦„), í•­ì²´ ê²€ì‚¬ê°€ ìŒì„±ì…ë‹ˆë‹¤.\n- **íŠ¹ì§•:**\n    - GAD65 Antibodies: **Negative** (ìê°€ë©´ì—­ ì•„ë‹˜)\n    - C-Peptide: **Detectable** (ì¸ìŠë¦° ìƒì‚°ì€ í•¨, ë¶„ë¹„ ê¸°ì „ì˜ ìœ ì „ì  ê²°í•¨ - Software problem)\n    - ê°€ì¡±ë ¥: **Autosomal Dominant (ìƒì—¼ìƒ‰ì²´ ìš°ì„±)** - 3ì„¸ëŒ€ì— ê±¸ì¹œ ìˆ˜ì§ ê°ì—¼ íŒ¨í„´.\n- **ì¹˜ë£Œ:** ì¸ìŠë¦° ì£¼ì‚¬ê°€ í•„ìš” ì—†ëŠ” ê²½ìš°ê°€ ë§ìŒ. ì„¤í¬ë‹ìš°ë ˆì•„(Sulfonylureas)ì— ë°˜ì‘ì´ ì¢‹ìŒ.\n---\n## 3. Diagnosis and Screening Game\n### ğŸ•µï¸â€â™‚ï¸ Who to Screen? (USPSTF Guidelines)\n- **ê¸°ë³¸:** 35~70ì„¸ ì„±ì¸ ì¤‘ ê³¼ì²´ì¤‘ ë˜ëŠ” ë¹„ë§Œ(BMI > 25)ì¸ ê²½ìš°.\n- **â˜… 35ì„¸ ë¯¸ë§Œ ì˜ˆì™¸ ì¡°í•­ (Under 35 Exception):** ê³¼ì²´ì¤‘ì´ë©´ì„œ ì¶”ê°€ ìœ„í—˜ ìš”ì¸ì´ ìˆëŠ” ê²½ìš° ì¦‰ì‹œ ì„ ë³„ ê²€ì‚¬.\n    - **HIV ê°ì—¼:** ë°”ì´ëŸ¬ìŠ¤ ìì²´ì˜ ì—¼ì¦ ë° í•­ë ˆíŠ¸ë¡œë°”ì´ëŸ¬ìŠ¤ì œ(ì•½ë¬¼)ì˜ ëŒ€ì‚¬ ë…ì„±.\n    - **ë‚­í¬ì„± ì„¬ìœ ì¦ (Cystic Fibrosis)**\n    - **ì¥ê¸° ì´ì‹ í›„ (Post-organ transplantation):** ë©´ì—­ì–µì œì œ(Tacrolimus, Cyclosporine, â˜…Steroids) ì‚¬ìš© ë•Œë¬¸. ìŠ¤í…Œë¡œì´ë“œëŠ” ê°„ì˜ í¬ë„ë‹¹ ìƒì„±ì„ ë†’ì´ê³  ê·¼ìœ¡ì˜ ì¸ìŠë¦° ì €í•­ì„±ì„ ìœ ë°œí•¨.\n    - **ì„ì‹  ê³„íš ì¤‘ì¸ ì—¬ì„±:** PCOS, ê°€ì¡±ë ¥ ë“± ìœ„í—˜ ìš”ì¸ì´ ìˆë‹¤ë©´ ì„ì‹  ì „ ê²€ì‚¬ í•„ìˆ˜.\n### ğŸ“Š Diagnostic Cut-offs (ìˆ˜ì¹˜ ì•”ê¸° í•„ìˆ˜)\n1. **Hemoglobin A1c:**\n    - **Diabetes:** â‰¥ 6.5%\n    - Pre-diabetes: 5.7% ~ 6.4%\n2. **Fasting Plasma Glucose (8ì‹œê°„ ê³µë³µ):**\n    - **Diabetes:** â‰¥ 126 mg/dL (ë§ë§‰ë³‘ì¦ ìœ ë³‘ë¥ ì´ ê¸‰ì¦í•˜ëŠ” êµ¬ê°„)\n    - Pre-diabetes: 100 ~ 125 mg/dL\n3. **Random Glucose (ìœ ì¦ìƒ í™˜ì):**\n    - **Diabetes:** â‰¥ 200 mg/dL + ê³ í˜ˆë‹¹ ì¦ìƒ (ë‹¤ìŒ, ë‹¤ë‡¨, ì²´ì¤‘ê°ì†Œ)\n4. **â˜… OGTT (75g ê²½êµ¬ í¬ë„ë‹¹ ë¶€í•˜ ê²€ì‚¬):**\n    - **Diabetes:** 2ì‹œê°„ í›„ í˜ˆë‹¹ â‰¥ 200 mg/dL\n    - **ì„ìƒì  ì˜ì˜:** **PCOS(ë‹¤ë‚­ì„± ë‚œì†Œ ì¦í›„êµ°)** í™˜ìì—ê²Œ ê°€ì¥ ë¯¼ê°í•œ(Most Sensitive) ê²€ì‚¬. PCOS í™˜ìëŠ” ê³µë³µ í˜ˆë‹¹ì´ë‚˜ A1cê°€ ì •ìƒì´ë¼ë„ ì‹í›„ ì¸ìŠë¦° ì €í•­ì„±ì´ ì‹¬í•  ìˆ˜ ìˆìŒ.\n---\n## 4. Health Maintenance Checklist (The Visit)\nëª¨ë“  ë°©ë¬¸ ì‹œ í™•ì¸í•´ì•¼ í•  ì‹œìŠ¤í…œ ì ê²€ ì‚¬í•­ì…ë‹ˆë‹¤.\n### ğŸ¯ Glycemic Control Goals\n- **ì¼ë°˜ ì„±ì¸:** A1c â‰¤ 7%\n- **â˜… ë…¸ì¸/ë™ë°˜ì§ˆí™˜ì:** A1c â‰¤ 8%\n    - ì´ìœ : **ì €í˜ˆë‹¹(Hypoglycemia)**ì´ ë” ìœ„í—˜í•¨. ë‚™ìƒ(ê³ ê´€ì ˆ ê³¨ì ˆ), ì–´ì§€ëŸ¬ì›€, ë¶€ì •ë§¥ ìœ ë°œ ê°€ëŠ¥. ì¹˜ë£Œê°€ ì§ˆë³‘ë³´ë‹¤ ë” ìœ„í—˜í•  ìˆ˜ ìˆìŒ.\n### ğŸ›¡ï¸ Organ Protection Screening\n1. **Nephropathy (ì‹ ì¥):**\n    - ê²€ì‚¬: ì—° 1íšŒ **Random Urine Albumin-to-Creatinine Ratio (UACR)**.\n    - ê¸°ì¤€: < 30 mg/g (ì •ìƒ). ê·¸ ì´ìƒì€ ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨(Microalbuminuria) â†’ ACE ì–µì œì œ ì‚¬ìš© ê³ ë ¤.\n2. **Retinopathy (ëˆˆ):**\n    - ê²€ì‚¬: ì•ˆê³¼ ì „ë¬¸ì˜ì— ì˜í•œ ì‚°ë™ ê²€ì‚¬(Dilated eye exam).\n    - **â˜… ì‹œê¸° (ì‹œí—˜ ë¹ˆì¶œ):**\n        - **Type 2:** ì§„ë‹¨ **ì¦‰ì‹œ (Right away)** (ì§„ë‹¨ ì „ ì´ë¯¸ ê³ í˜ˆë‹¹ ê¸°ê°„ì´ ê¸¸ì—ˆìŒ).\n        - **Type 1:** ì§„ë‹¨ í›„ **5ë…„ ë’¤**ë¶€í„° (ë§ë§‰ë³‘ì¦ ë°œìƒì— ì‹œê°„ì´ ê±¸ë¦¼).\n3. **Neuropathy (ì‹ ê²½):**\n    - ê²€ì‚¬: ì—° 1íšŒ ë°œ ê²€ì‚¬ (Monofilament + Tuning fork).\n4. **Cardiovascular (ì‹¬í˜ˆê´€):**\n    - í˜ˆì•• ì¡°ì ˆ (<130/80), ì§€ì§ˆ ê´€ë¦¬(Statins), ê¸ˆì—°, ì•„ìŠ¤í”¼ë¦° ë“±. ë‹¹ë‡¨ í™˜ìì˜ ì£¼ ì‚¬ë§ ì›ì¸ì€ ì‹¬ì¥ ì§ˆí™˜ì„.\n---\n## 5. Complications Deep Dive ğŸ¦µğŸ§ ğŸ¤¢\n### âš¡ Neuropathy (ì‹ ê²½ë³‘ì¦)\në‹¨ìˆœíˆ \"ë°œ ì €ë¦¼\"ì´ ì•„ë‹™ë‹ˆë‹¤.\n1. **Cardiovascular Autonomic Neuropathy (DAN):**\n    - **Resting Tachycardia:** ë¯¸ì£¼ì‹ ê²½(Vagal tone) ì†Œì‹¤ë¡œ ì‹¬ë°•ìˆ˜ ì¦ê°€.\n    - **Loss of Nocturnal Dipping:** ë°¤ì— í˜ˆì••ì´ ë–¨ì–´ì§€ì§€ ì•ŠìŒ.\n    - **Postural Hypotension:** ê¸°ë¦½ì„± ì €í˜ˆì••.\n2. **Genitourinary (ë¹„ë‡¨ìƒì‹ê¸°):**\n    - ë°œê¸° ë¶€ì „, ì—­í–‰ì„± ì‚¬ì •.\n    - **Neurogenic Bladder (ì‹ ê²½ì¸ì„± ë°©ê´‘):** ë°©ê´‘ ì¶©ë§Œ ê°ê° ì†Œì‹¤ â†’ ì†Œë³€ì´ ê°€ë“ ì°¨ë„ ëª¨ë¦„ â†’ Overflow Incontinence (ì—­ë¥˜ì„± ìš”ì‹¤ê¸ˆ) â†’ ì¦ì€ ìš”ë¡œê°ì—¼(UTI).\n3. **Peripheral Neuropathy (ë§ì´ˆ):**\n    - **ê²€ì‚¬ ë„êµ¬:**\n        - **Monofilament (10g force):** ì••ê°(Pressure sensation) ì¸¡ì •. ê¶¤ì–‘(Ulcer) ë°œìƒ ìœ„í—˜ ì˜ˆì¸¡ì— ì¤‘ìš”.\n        - **Tuning Fork:** ì§„ë™ê°ê°(Vibratory sense) ì¸¡ì •. ëŒ€ì„¬ìœ  ì‹ ê²½ ì†ìƒì˜ ì´ˆê¸° ì§•í›„.\n    - **Charcot Arthropathy:** ê°ê° ì†Œì‹¤ë¡œ ì¸í•œ ë¼ˆì™€ ê´€ì ˆì˜ íŒŒê´´. **\"Rocker bottom foot\"** ë³€í˜• ìœ ë°œ.\n### ğŸ¤¢ Gastroparesis (ìœ„ë§ˆë¹„)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-61","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","tree"]}
{"chunk_type":"transcript_chunk","text":"- **ì •ì˜:** ë¯¸ì£¼ì‹ ê²½ ì†ìƒìœ¼ë¡œ ìœ„ ë°°ì¶œì´ ì§€ì—°ë¨.\n- **ì¦ìƒ:** ì˜¤ì‹¬, êµ¬í† , ì¡°ê¸° í¬ë§Œê°.\n- **â˜… \"A-ha\" Vignette Clue (ì‹œí—˜ ê²°ì •ì  ë‹¨ì„œ):**\n    - ì¸ìŠë¦° ì˜ì¡´ì„± ë‹¹ë‡¨ í™˜ìê°€ ì‹í›„ ì˜¤ì‹¬/êµ¬í† ë¥¼ í˜¸ì†Œí•˜ë©° **\"ì‹í›„ ì €í˜ˆë‹¹(Post-prandial Hypoglycemia)\"**ì„ ê²ªìŒ.\n    - **ê¸°ì „ (Mismatch):** ì†íš¨ì„± ì¸ìŠë¦°ì€ íˆ¬ì—¬ë˜ì–´ ì‘ìš©(Peak)í•˜ì§€ë§Œ, ìœ„ë§ˆë¹„ë¡œ ìŒì‹ì€ ì†Œí™”/í¡ìˆ˜ë˜ì§€ ì•ŠìŒ â†’ í˜ˆë‹¹ì„ ì˜¬ë¦´ ìŒì‹ì´ ì—†ëŠ”ë° ì¸ìŠë¦°ë§Œ ì‘ìš©í•˜ì—¬ ì €í˜ˆë‹¹ ë°œìƒ.\n---\n## 6. Acute Decompensation: DKA (Diabetic Ketoacidosis)\n### ğŸš¨ Clinical Presentation\n- **í™˜ì:** ì£¼ë¡œ ì Šì€ 1í˜• ë‹¹ë‡¨ í™˜ì (Brittle diabetes).\n- **ì´ˆê¸° ì¦ìƒ:** ê·¹ì‹¬í•œ ë‹¤ë‡¨, ë‹¤ìŒ, **ì‹œë ¥ ì €í•˜(Blurred Vision)**.\n    - *ì‹œë ¥ ì €í•˜ ì´ìœ :* ê³ í˜ˆë‹¹ìœ¼ë¡œ ì¸í•œ ì‚¼íˆ¬ì•• ë³€í™”ë¡œ ìˆ˜ì •ì²´(Lens)ì˜ ìˆ˜ë¶„ì´ ë¹ ì ¸ë‚˜ê°€ ëª¨ì–‘ì´ ë³€í•¨ (êµ´ì ˆë¥  ë³€í™”).\n- **í›„ê¸° ì¦ìƒ:** ì¿ ìŠ¤ë§ˆìš¸ í˜¸í¡(Kussmaul respirations), ê³¼ì¼ ëƒ„ìƒˆ(Fruity breath), ì˜ì‹ ë³€í™”.\n### ğŸ’¡ Interesting Concept: Stress Hyperglycemia\n- íŠ¸ë¼ìš°ë§ˆë‚˜ ìˆ˜ìˆ  í›„ í™˜ìì˜ í˜ˆë‹¹ ìƒìŠ¹ì€ **ìƒì¡´ ê¸°ì „(Survival mechanism)**ì¼ ìˆ˜ ìˆìŒ.\n- ë¶€ìƒ ì‹œ ë©´ì—­ ì²´ê³„ì™€ ë‡Œì— ì—°ë£Œë¥¼ ê³µê¸‰í•˜ê¸° ìœ„í•´ ì‹ ì²´ê°€ ì˜ë„ì ìœ¼ë¡œ ì¸ìŠë¦° ì €í•­ì„±ì„ ë†’ì—¬ í˜ˆë‹¹ì„ ì˜¬ë¦¼. ì´ëŠ” ì§ˆë³‘ì´ ì•„ë‹ˆë¼ ì ì‘ ë°˜ì‘ì„.\n---\n## ğŸ”¥ Rapid Fire Recap: The \"Must-Knows\"\n1. **Subtypes:** ë‚˜ì´ê°€ ì•„ë‹ˆë¼ **ìƒí™”í•™ì  ì¦ê±°(C-peptide, Antibodies)**ë¡œ êµ¬ë¶„í•˜ë¼.\n2. **Screening:** 35-70ì„¸ ê³¼ì²´ì¤‘ì´ ê¸°ë³¸ì´ì§€ë§Œ, **HIV, ë‚­í¬ì„± ì„¬ìœ ì¦, ì´ì‹ í™˜ì, PCOS**ëŠ” 35ì„¸ ë¯¸ë§Œì´ë¼ë„ ì„ ë³„ ê²€ì‚¬í•˜ë¼.\n3. **PCOS:** ì§„ë‹¨ì„ ìœ„í•´ **OGTT**ë¥¼ ì‚¬ìš©í•˜ë¼ (ê°€ì¥ ë¯¼ê°í•¨).\n4. **Gastroparesis:** ì¸ìŠë¦° ì˜ì¡´ í™˜ìì˜ **ì‹í›„ ì €í˜ˆë‹¹ + ì†Œí™”ê¸° ì¦ìƒ**ì„ ì°¾ì•„ë¼.\n5. **Neuropathy:** MonofilamentëŠ” ê¶¤ì–‘ ìœ„í—˜ì„, Tuning forkëŠ” ì§„ë™ ê°ê°ì„ ë³¸ë‹¤.\n6. **Retinopathy:** 2í˜• ë‹¹ë‡¨ëŠ” ì§„ë‹¨ ì¦‰ì‹œ, 1í˜• ë‹¹ë‡¨ëŠ” 5ë…„ í›„ ê²€ì‚¬í•œë‹¤.\n**Final Thought:** \"Insulin resistance is a fundamental response to injury and stress.\" (ì¸ìŠë¦° ì €í•­ì„±ì€ ì†ìƒê³¼ ìŠ¤íŠ¸ë ˆìŠ¤ì— ëŒ€í•œ ê·¼ë³¸ì ì¸ ë°˜ì‘ì´ë‹¤.)\n---\n# USMLE Step 2 Deep Dive: Diabetes Pharmacology & Acute Management\nì´ ê°•ì˜ëŠ” ë‹¨ìˆœíˆ ë‹¹ë‡¨ë³‘ì˜ ì •ì˜ë¥¼ ë„˜ì–´ì„œ, **USMLE Step 2**ë¥¼ ëª©ì „ì— ë‘” í•™ìŠµìë¥¼ ìœ„í•´ **\"How(ì–´ë–»ê²Œ ê´€ë¦¬í•  ê²ƒì¸ê°€)\"**ì— ì§‘ì¤‘í•©ë‹ˆë‹¤. ê¸‰ì„± ìœ„ê¸° ê´€ë¦¬(DKA/HHS)ë¶€í„° ë³µì¡í•œ ì•½ë¦¬í•™, ê·¸ë¦¬ê³  í•©ë³‘ì¦ ê´€ë¦¬ê¹Œì§€ ë‹¤ë£¹ë‹ˆë‹¤.\n## 1. The Acute Crisis: DKA vs. HHS ğŸš¨\nì‘ê¸‰ì‹¤(ER) ì„¸íŒ…ì—ì„œ ê°€ì¥ ë¨¼ì € ë§ˆì£¼í•˜ê²Œ ë˜ëŠ” ë‘ ê°€ì§€ ì¹˜ëª…ì ì¸ ê¸‰ì„± í•©ë³‘ì¦ì…ë‹ˆë‹¤. ë³‘íƒœìƒë¦¬ë¥¼ ì´í•´í•˜ë©´ ì¹˜ë£Œ í”„ë¡œí† ì½œì´ ì§ê´€ì ìœ¼ë¡œ ì´í•´ë©ë‹ˆë‹¤.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-81","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","treatment","pathophysiology"]}
{"chunk_type":"transcript_chunk","text":"### A. Diabetic Ketoacidosis (DKA) - Type 1 ìœ„ì£¼\n- **Pathophysiology (The Triad):**\n    1. **Hyperglycemia (ê³ í˜ˆë‹¹)**\n    2. **Ketosis (ì¼€í†¤ì¦):** ì¸ìŠë¦° ê²°í• â†’ ì„¸í¬ê°€ ë‹¹ì„ ëª» ì”€ â†’ ì§€ë°© ë¶„í•´(Lipolysis) â†’ ìœ ë¦¬ì§€ë°©ì‚°(Free Fatty Acids) ê°„ìœ¼ë¡œ ì´ë™ â†’ ì¼€í†¤ì²´(Ketone bodies) ìƒì„±.\n        - ì£¼ìš” ì¼€í†¤: Acetoacetate, **Beta-hydroxybutyrate (â˜… Acidosisì˜ ì£¼ë²”)**.\n    3. **Acidosis (ì‚°ì¦):** ì¼€í†¤ ì¶•ì  â†’ H+ ì´ì˜¨ ë°©ì¶œ â†’ Bicarbonateê°€ ë²„í¼ë§í•˜ë ¤ë‹¤ ê³ ê°ˆë¨ â†’ **Anion Gap Metabolic Acidosis**.\n- **Clinical Presentation:** ë‹¤ë‡¨(Polyuria), ë‹¤ìŒ(Polydipsia), ë³µí†µ(Abdominal pain), blurry vision â˜… , êµ¬ì—­/êµ¬í† (N/V), **Kussmaul respirations** (CO2ë¥¼ ë‚ ë ¤ ë³´ë‚´ë ¤ëŠ” ê¹Šê³  ë¹ ë¥¸ í˜¸í¡), **Fruity odor** (Acetone ëƒ„ìƒˆ).\n### B. Hyperosmolar Hyperglycemic State (HHS) - Type 2 ìœ„ì£¼\n- **íŠ¹ì§•:** ì•½ê°„ì˜ ì¸ìŠë¦°ì€ ë‚¨ì•„ìˆì–´ì„œ Ketogenesis(ì¼€í†¤ ìƒì„±)ëŠ” ì–µì œí•¨. ë”°ë¼ì„œ Acidosisë‚˜ Anion Gapì€ ì—†ìŒ.\n- **ë¬¸ì œì :** í˜ˆë‹¹ì´ **800~1000 mg/dL** ì´ìƒìœ¼ë¡œ ì¹˜ì†ŸìŒ â†’ ì—„ì²­ë‚œ ê³ ì‚¼íˆ¬ì••(Hyperosmolarity) â†’ ì‹¬ê°í•œ íƒˆìˆ˜.\n- **ì¦ìƒ:** **Neurologic signs** (Confusion, Lethargy, Coma)ê°€ í›¨ì”¬ ëšœë ·í•¨.\n---\n## 2. Management Protocol: The \"How-To\" ğŸ¥\nDKAì™€ HHS ì¹˜ë£Œì˜ í•µì‹¬ì€ ìˆœì„œì…ë‹ˆë‹¤. **Fluid â†’ Potassium â†’ Insulin** ìˆœì„œë¥¼ ê¸°ì–µí•˜ì„¸ìš”.\n### Step 1: Fluids (ìˆ˜ë¶„ ê³µê¸‰) ğŸ’§\n- í™˜ìëŠ” ì—„ì²­ë‚œ íƒˆìˆ˜ ìƒíƒœ(Osmotic diuresisë¡œ ì¸í•´ 5~10L ë¶€ì¡±).\n- **ì²« ì¡°ì¹˜:** **Isotonic Saline (Normal Saline)** Bolus (1~2L in first 1-2 hrs)ë¡œ í˜ˆê´€ ë‚´ ë³¼ë¥¨(Intravascular volume) íšŒë³µ.\n### Step 2: The Potassium Trap (â˜… High Yield) ğŸŒ\n- ê°€ì¥ ì¤‘ìš”í•œ ë³´ë“œ ë¬¸ì œ í¬ì¸íŠ¸ì…ë‹ˆë‹¤. ì´ˆê¸° ë© ê²°ê³¼ì—ì„œ í¬íƒ€ìŠ˜(K+)ì´ ì •ìƒì´ê±°ë‚˜ ë†’ì•„ ë³´ì—¬ë„ **ì ˆëŒ€ë¡œ ì†ì§€ ë§ˆì„¸ìš”(Total body depletion ìƒíƒœ)**.\n- Acidosisë¡œ ì¸í•´ ì„¸í¬ ë‚´ì˜ K+ê°€ í˜ˆì•¡ìœ¼ë¡œ ë¹ ì ¸ë‚˜ì˜¨ ìƒíƒœì…ë‹ˆë‹¤. ì¸ìŠë¦°ì„ ì£¼ë©´ K+ê°€ ë‹¤ì‹œ ì„¸í¬ ì•ˆìœ¼ë¡œ ê¸‰ê²©íˆ ë“¤ì–´ê°€ **Fatal Arrhythmia**ë¥¼ ìœ ë°œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- ì‹¤ì œë¡œëŠ” hypokalemiaì¸ë° ê²€ì‚¬ìƒ ë†’ì•„ë³´ì´ëŠ” ì°©ê°ì¸ê²ƒ.\n- **Algorithm (Rule of 3.3):**\n    - **K+ < 3.3:** **Insulin ê¸ˆì§€!** K+ë¥¼ ë¨¼ì € ë³´ì¶©.\n    - **K+ 3.3 ~ 5.2:** K+ë¥¼ ë³´ì¶©í•˜ë©´ì„œ Insulin ì‹œì‘.\n    - **K+ > 5.2:** Insulin ì‹œì‘ (K+ ëª¨ë‹ˆí„°ë§).\n### Step 3: Insulin ğŸ’‰\n- **IV Regular Insulin** (0.1 units/kg/hr) ì‚¬ìš©.\n- **ëª©í‘œ:** í˜ˆë‹¹ì„ ì‹œê°„ë‹¹ 50~75 mg/dLì”© ì²œì²œíˆ ë‚®ì¶¤. ë„ˆë¬´ ë¹¨ë¦¬ ë‚®ì¶”ë©´ **Cerebral Edema (ë‡Œë¶€ì¢…)** ìœ„í—˜!\n- **Closing the Gap:** í˜ˆë‹¹ì´ 200~250 mg/dLê¹Œì§€ ë–¨ì–´ì ¸ë„ Anion Gapì´ ë‹«íˆì§€ ì•Šì•˜ë‹¤ë©´(Acidosis í•´ê²° ì•ˆ ë¨), ì¸ìŠë¦°ì„ ë„ì§€ ë§ê³  **IV fluidsì— Dextrose(D5W)ë¥¼ ì¶”ê°€**í•´ì„œ ì¸ìŠë¦°ì„ ê³„ì† ì£¼ì…í•´ì•¼ í•¨ (Sugarë¥¼ ë¨¹ì—¬ê°€ë©° ì¸ìŠë¦°ì„ ì¤Œ).\n### Step 4: Transition\n- Gapì´ ë‹«íˆê³  í™˜ìê°€ ì‹ì‚¬ ê°€ëŠ¥í•˜ë©´ í”¼í•˜(SubQ) ì¸ìŠë¦°ìœ¼ë¡œ ì „í™˜.\n- **Overlap bridge:** IV ë„ê¸° 1~2ì‹œê°„ ì „ì— SubQ(Long-acting)ë¥¼ ì¤˜ì„œ ì¸ìŠë¦° ê³µë°±ì„ ë§‰ì•„ì•¼ í•¨(Rebound DKA ë°©ì§€).\n---\n## 3. Pharmacology: The Drug Classes ğŸ’Š\nì•½ë¬¼ ê¸°ì „, ë¶€ì‘ìš©, ê¸ˆê¸° ì‚¬í•­ì„ ì™„ë²½íˆ ë§¤ì¹­í•´ì•¼ í•©ë‹ˆë‹¤.\n| **ì•½ë¬¼ ê³„ì—´** | **ê¸°ì „ ë° íŠ¹ì§•** | **â˜… Key Side Effects / Notes** |\n| --- | --- | --- |\n| **Biguanides**\n(Metformin) | **1st Line.** ê°„ì˜ í¬ë„ë‹¹ ìƒì„±(Gluconeogenesis) ì–µì œ. ì¸ìŠë¦° ê°ìˆ˜ì„± ê°œì„ . | â€¢ **Lactic Acidosis:** ì‹ ì¥/ê°„ ê¸°ëŠ¥ ì €í•˜ ì‹œ ìœ„í—˜.\nâ€¢ **eGFR < 30:** ê¸ˆê¸° (Contraindication).\nâ€¢ GI Upset (ì„¤ì‚¬ ë“±), B12 ê²°í•.\nâ€¢ **Weight Neutral** (ì•½ê°„ì˜ ê°ì†Œ). |\n| **Sulfonylureas**\n(Glipizide, Glimepiride, Glyburide) (ëˆì—†ìœ¼ë©´) | ì·Œì¥ ë² íƒ€ì„¸í¬ ìê·¹ (K+ ì±„ë„ ì°¨ë‹¨ â†’ Ca ìœ ì… â†’ ì¸ìŠë¦° ë¶„ë¹„). \"Squeeze the pancreas.\" | â€¢ **Hypoglycemia** (ê°€ì¥ í° ìœ„í—˜).\nâ€¢ **Weight Gain**.\nâ€¢ **Glyburide:** ì‹ ë¶€ì „ í™˜ì ê¸ˆê¸° (í™œì„± ëŒ€ì‚¬ì²´ ì¶•ì ). |\n| **TZDs**\n(Pioglitazone) | **PPAR-gamma agonist** (í•µ ìˆ˜ìš©ì²´). ì¸ìŠë¦° ë¯¼ê°ë„ ì¦ê°€. | â€¢ **Fluid Retention/Edema:** **CHF Class 3/4 í™˜ì ì ˆëŒ€ ê¸ˆê¸°!**\nâ€¢ ê³¨ì ˆ ìœ„í—˜ ì¦ê°€, ì²´ì¤‘ ì¦ê°€.\nâ€¢ ë°©ê´‘ì•” ì´ìŠˆ(ê³¼ê±°). |\n| **GLP-1 Agonists**\n(-tides: Exenatide, Liraglutide, Semaglutide) | \"The Darlings.\" í¬ë„ë‹¹ ì˜ì¡´ì„± ì¸ìŠë¦° ë¶„ë¹„â†‘, ê¸€ë£¨ì¹´ê³¤â†“, ìœ„ ë°°ì¶œ ì§€ì—°. | â€¢ **Weight Loss** (Satiety ì¦ê°€).\nâ€¢ **CV Benefit** (ì‹¬í˜ˆê´€ ë³´í˜¸).\nâ€¢ GI ë¶€ì‘ìš©(N/V) í”í•¨.\nâ€¢ **Contraindication:** Medullary Thyroid Cancer (MEN 2) ê³¼ê±°ë ¥/ê°€ì¡±ë ¥. |\n| **DPP-4 Inhibitors**\n(-gliptins: Sitagliptin, Linagliptin) | GLP-1 ë¶„í•´ íš¨ì†Œ ì–µì œ. GLP-1 íš¨ê³¼ ì—°ì¥. | â€¢ Weight Neutral, ì˜ ê²¬ë”¤(Gentle).\nâ€¢ Pancreatitis ìœ„í—˜ì„±(ì•½í•¨).\nâ€¢ ì‹¬ë¶€ì „ ìœ„í—˜ ì‹ í˜¸(Saxagliptin). |\n| **SGLT2 Inhibitors**\n(-flozins: Empagliflozin, Dapagliflozin) | ì‹ ì¥(PCT)ì—ì„œ í¬ë„ë‹¹ ì¬í¡ìˆ˜ ì°¨ë‹¨ â†’ ì†Œë³€ìœ¼ë¡œ ë‹¹ ë°°ì¶œ. | â€¢ **Weight Loss**, í˜ˆì•• ê°ì†Œ.\nâ€¢ **Renal & Cardiac Protective** (CKD, HF í™˜ìì— ê°•ë ¥ ì¶”ì²œ).\nâ€¢ **UTI, Yeast Infection** (ê³°íŒ¡ì´ ê°ì—¼).\nâ€¢ â˜… **Euglycemic DKA:** í˜ˆë‹¹ì´ ì •ìƒì´ì§€ë§Œ DKA ë°œìƒ ê°€ëŠ¥. |\n---","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-101","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"transcript_chunk","text":"## 4. Insulin Types & Strategy ğŸ’‰\n### **Types**\n- **Basal (Long-acting):** Glargine, Degludec. \"Peakless\" (í”¼í¬ ì—†ì´ 24ì‹œê°„ ì§€ì†). ë°°ê²½ ì¸ìŠë¦° ìš”êµ¬ëŸ‰ ì»¤ë²„.\n- **Bolus (Rapid-acting):** Lispro, Aspart, Glulisine. ì‹ì‚¬ ì§ì „ íˆ¬ì—¬. 15ë¶„ ë‚´ ì‘ìš© ì‹œì‘.\n- Intermediate (NPH): peakìˆìŒ. ì˜ ì•ˆì”€. hypoglycemiaìœ„í—˜.\n- RI: ì˜ ì•ˆì”€. DKA, HHS ë•Œ ì”€. Inpatient IV drip ë•ŒëŠ” ì”€.\n### **Management Strategy**\n- **Inpatient (ì…ì› í™˜ì):** ê²½êµ¬ì•½(Oral meds)ì€ ëŠìŠµë‹ˆë‹¤.\n    - **Basal-Bolus ìš”ë²•**ì´ Sliding Scale ë‹¨ë… ìš”ë²•ë³´ë‹¤ í›¨ì”¬ ìš°ì›”í•©ë‹ˆë‹¤.\n    - **Correction Scale:** ì‹ì „ í˜ˆë‹¹ì— ë”°ë¼ ì¶”ê°€ë¡œ ì£¼ëŠ” ì¸ìŠë¦°.\n---\n## 5. T2DM Outpatient Management Algorithm (ì™¸ë˜ ì¹˜ë£Œ ì•Œê³ ë¦¬ì¦˜) ğŸš€\në‹¨ìˆœíˆ ì•½ë¬¼ ì¢…ë¥˜ë¥¼ ì•„ëŠ” ê²ƒë³´ë‹¤ **\"ì–´ë–¤ í™˜ìì—ê²Œ ë¬´ì—‡ì„ ë¨¼ì € ì“¸ ê²ƒì¸ê°€?\"**ë¥¼ ê²°ì •í•˜ëŠ” ê²ƒì´ ì‹œí—˜ì˜ í•µì‹¬ì…ë‹ˆë‹¤.\n- ê°œì¸í™”ëœ hba1c ëª©í‘œ\n    - ì¼ë°˜ì ìœ¼ë¡œ 7%\n    - ê±´ê°•í•˜ê³  ì Šì€ í™˜ì 6.5%\n    - comorbididities, ë…¸ì¸ 8%\n### 1.1  Step 1: The Anchor (1ë‹¨ê³„: ì‹œì‘ì€ ë©”íŠ¸í¬ë¥´ë¯¼)\n- **Standard of Care:** ì§„ë‹¨ ì¦‰ì‹œ ìƒí™œìŠµê´€ êµì •(Lifestyle)ê³¼ í•¨ê»˜ **Metformin**ì„ ì‹œì‘í•©ë‹ˆë‹¤.\n- **ì˜ˆì™¸ (Exceptions):**\n    - eGFR < 30 (CKD stage 4, 5).\n    - Acidosis risk (ì‹¬í•œ ê°„ë¶€ì „ ë“±).\n### 1.2. Step 2: Escalation Strategy (2ë‹¨ê³„: ì•½ë¬¼ ì¶”ê°€) ğŸ“ˆ\n3ê°œì›” ë’¤ A1cê°€ ëª©í‘œ(ì£¼ë¡œ < 7%)ì— ë„ë‹¬í•˜ì§€ ëª»í–ˆë‹¤ë©´, **ë‘ ë²ˆì§¸ ì•½ì œ**ë¥¼ ì¶”ê°€í•©ë‹ˆë‹¤. ì´ë•Œ ì„ íƒ ê¸°ì¤€ì€ **ë™ë°˜ ì§ˆí™˜(Comorbidities)**ì…ë‹ˆë‹¤.\n| **í™˜ìì˜ ë™ë°˜ ì§ˆí™˜ (Comorbidity)** | **ì¶”ì²œ ì•½ë¬¼ (Drug of Choice)** | **ì´ìœ  (Rationale)** |\n| --- | --- | --- |\n| **Heart Failure (ì‹¬ë¶€ì „)** ğŸ«€ | **SGLT-2 Inhibitor** (Empagliflozin ë“±) | ì‹¬ë¶€ì „ ì…ì› ë° ì‚¬ë§ë¥  ê°ì†Œ ì…ì¦. |\n| **CKD (ë§Œì„± ì‹ ë¶€ì „)** ì½©íŒ¥ | **SGLT-2 Inhibitor** | ì‹ ì¥ ê¸°ëŠ¥ ì•…í™” ì§€ì—° (Nephroprotection). |\n| **ASCVD (ì£½ìƒê²½í™” ì‹¬í˜ˆê´€ì§ˆí™˜)** ğŸ©¸\n(MI, Stroke, CAD ë³‘ë ¥) | **GLP-1 Agonist** or **SGLT-2 Inhibitor** | ì£¼ìš” ì‹¬í˜ˆê´€ ì‚¬ê±´(MACE) ì˜ˆë°© íš¨ê³¼. |\n| **Obesity (ë¹„ë§Œ)** âš–ï¸ | **GLP-1 Agonist** (Semaglutide ë“±) | ê°•ë ¥í•œ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼. |\n| **Cost Issues (ë¹„ìš© ë¬¸ì œ)** ğŸ’¸ | **Sulfonylurea** or **TZD** | ì•½ê°’ì´ ë§¤ìš° ì €ë ´í•¨ (ë‹¨, ì €í˜ˆë‹¹/ì²´ì¤‘ì¦ê°€ ìœ„í—˜ ê°ìˆ˜). |\n### 1.3. â˜… The \"Insulin First\" Rule (ì–¸ì œ ë°”ë¡œ ì¸ìŠë¦°ì„ ì“°ëŠ”ê°€?) ğŸš¨\nê²½êµ¬ ì•½ë¬¼ì„ ê±´ë„ˆë›°ê³  **ì§„ë‹¨ ì¦‰ì‹œ ì¸ìŠë¦°**ì„ ì¨ì•¼ í•˜ëŠ” ê²½ìš°ì…ë‹ˆë‹¤.\n- **ê¸°ì¤€ (Criteria):**\n    1. **ì²˜ìŒì— HbA1c > 10%**\n    2. **Random Glucose > 300 mg/dL**\n    3. **Severe Symptoms (Catabolic State):** ë‹¤ìŒ(Polydipsia), ë‹¤ë‡¨(Polyuria), **ì²´ì¤‘ ê°ì†Œ(Weight loss)**.\n- **ì´ìœ :** í¬ë„ë‹¹ ë…ì„±(Glucotoxicity)ì´ ë„ˆë¬´ ì‹¬í•´ ê²½êµ¬ ì•½ë¬¼ì´ ë“£ì§€ ì•Šê±°ë‚˜, ì·Œì¥ ë² íƒ€ì„¸í¬ê°€ ê±°ì˜ ê³ ê°ˆëœ ìƒíƒœ(Catabolic)ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¼ë‹¨ ì¸ìŠë¦°ìœ¼ë¡œ ë¶ˆì„ ëˆ ë’¤(Break toxicity), ë‚˜ì¤‘ì— ê²½êµ¬ì•½ìœ¼ë¡œ ì „í™˜(De-escalate)ì„ ê³ ë ¤í•©ë‹ˆë‹¤.\n- ê²½êµ¬ì•½ìœ¼ë¡œ ë¶ˆì¶©ë¶„í•˜ì—¬ ë³´ì¶©í•˜ëŠ” ê²½ìš°\n    - Basal ì¶”ê°€ë¶€í„° ì‹œì‘í•œë‹¤.\n---\n## 6. Diabetic Nephropathy","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-121","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"### 1. Pathophysiology: The Pressure Cooker (ê¸°ì „)\nê°•ì‚¬ëŠ” ì‹ ì¥ ì†ìƒì˜ ì‹œì‘ì„ **'ì••ë ¥ì†¥(Pressure Cooker)'**ì— ë¹„ìœ í•˜ì—¬ ì„¤ëª…í•©ë‹ˆë‹¤.\n- **Hyperfiltration (ê³¼ì—¬ê³¼):**\n    - ì´ˆê¸° ë‹¨ê³„ì—ì„œ ê³ í˜ˆë‹¹ì€ ì‹ ì¥ìœ¼ë¡œ ê°€ëŠ” í˜ˆë¥˜ë¥¼ ì¦ê°€ì‹œí‚µë‹ˆë‹¤.\n    - ì´ë¡œ ì¸í•´ ì‚¬êµ¬ì²´(Glomerulus) ë‚´ë¶€ì˜ ì••ë ¥ì´ ë†’ì•„ì§€ê³ , ì‹ ì¥ì€ í‰ì†Œë³´ë‹¤ ë” ë§ì€ ì¼ì„ í•˜ê²Œ ë©ë‹ˆë‹¤(Hyperfiltration).\n- **Damage (ì†ìƒ):**\n    - ë†’ì€ ì••ë ¥ì´ ì§€ì†ë˜ë©´ ì‚¬êµ¬ì²´ ê¸°ì €ë§‰ì´ ì†ìƒë˜ê³ , ê²°êµ­ êµ¬ë©ì´ ì»¤ì ¸ì„œ ë‹¨ë°±ì§ˆ(ì•Œë¶€ë¯¼)ì´ ì†Œë³€ìœ¼ë¡œ ìƒˆì–´ ë‚˜ì˜¤ê²Œ ë©ë‹ˆë‹¤.\n    - ì´ê²ƒì´ ë°”ë¡œ **Microalbuminuria (ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨)**ì…ë‹ˆë‹¤.\n### 2. Screening: Catching it Early (ì„ ë³„ ê²€ì‚¬) ğŸ•µï¸â€â™‚ï¸\nê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ì‹ ì¥ ê¸°ëŠ¥(Cr)ì´ ë–¨ì–´ì§€ê¸° **ì „**ì—, ë¯¸ì„¸í•œ ì†ìƒ ì§•í›„ë¥¼ ì°¾ì•„ë‚´ëŠ” ê²ƒì…ë‹ˆë‹¤.\n- **The Test:** **Spot Urine Albumin/Creatinine Ratio (UACR)**\n    - â˜… **Dipstick is Useless:** ì¼ë°˜ ì†Œë³€ê²€ì‚¬ ìŠ¤í‹±(Dipstick)ì€ 'ë¯¸ì„¸' ì•Œë¶€ë¯¼ë‡¨ë¥¼ ì¡ì•„ë‚´ì§€ ëª»í•©ë‹ˆë‹¤. ë°˜ë“œì‹œ **UACR** ì •ëŸ‰ ê²€ì‚¬ë¥¼ í•´ì•¼ í•©ë‹ˆë‹¤.\n- **The Cutoff:**\n    - **Normal:** < 30 mg/g\n    - **Microalbuminuria (Moderately increased):** **30 - 300 mg/g**\n    - **Macroalbuminuria (Severely increased):** > 300 mg/g\n    - **ì§„ë‹¨ ê¸°ì¤€:** UACRì´ **30 mg/g ì´ìƒ**ì´ë©´ ë‹¹ë‡¨ë³‘ì„± ì‹ ì¦ì˜ ì´ˆê¸° ì§•í›„ë¡œ ê°„ì£¼í•©ë‹ˆë‹¤.\n- **When to Screen (ê²€ì‚¬ ì‹œê¸°):**\n    - **Type 2 DM:** **ì§„ë‹¨ ì¦‰ì‹œ (At diagnosis)** ì‹œì‘í•˜ì—¬ ë§¤ë…„ ê²€ì‚¬. (ì œ2í˜•ì€ ì§„ë‹¨ ì‹œì ì— ì´ë¯¸ ì•“ì€ ì§€ ì˜¤ë˜ë˜ì—ˆì„ ìˆ˜ ìˆê¸° ë•Œë¬¸).\n    - **Type 1 DM:** **ì§„ë‹¨ 5ë…„ í›„**ë¶€í„° ì‹œì‘. (ê¸‰ì„± ë°œë³‘ì´ë¯€ë¡œ ì´ˆê¸° 5ë…„ì€ ì‹ ì¥ í•©ë³‘ì¦ì´ ë“œë¬¾).\n### 3. Treatment: Turning Down the Pressure (ì¹˜ë£Œ) ğŸ’Š\nì¹˜ë£Œì˜ í•µì‹¬ì€ ì‚¬êµ¬ì²´ ë‚´ë¶€ì˜ ì••ë ¥ì„ ë‚®ì¶°ì„œ ì½©íŒ¥ì„ ë³´í˜¸í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.\n### 3.1. ACE Inhibitors & ARBs (The Gold Standard) ğŸ†\n- **ì•½ë¬¼:** Lisinopril, Losartan ë“±.\n- **Indication (ì ì‘ì¦):**\n    - **ê³ í˜ˆì••ì´ ì—†ë”ë¼ë„(Normotensive)**, **ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨(Microalbuminuria)ê°€ ê²€ì¶œë˜ë©´ ë¬´ì¡°ê±´ ì‹œì‘**í•©ë‹ˆë‹¤.\n    - ì´ëŠ” í˜ˆì•• ì¡°ì ˆ ëª©ì ì´ ì•„ë‹ˆë¼ ì‹ ì¥ ë³´í˜¸ ëª©ì ì…ë‹ˆë‹¤.\n- **Mechanism (ê¸°ì „):**\n    - **Efferent Arteriole Dilation (ìˆ˜ì¶œ ì†Œë™ë§¥ í™•ì¥):** ë‚˜ê°€ëŠ” í˜ˆê´€ì„ ë„“í˜€ì£¼ì–´ ì‚¬êµ¬ì²´ ë‚´ë¶€ì˜ ì••ë ¥ì„ ë–¨ì–´ëœ¨ë¦½ë‹ˆë‹¤. (ë§ˆì¹˜ ëŒì˜ ìˆ˜ë¬¸ì„ ì—´ì–´ ìˆ˜ìœ„ë¥¼ ë‚®ì¶”ëŠ” ì›ë¦¬).\n### 3.2. í˜ˆë‹¹ ì¡°ì ˆ SGLT-2 Inhibitors (The New Champion) ğŸŒŸ\n- **ì•½ë¬¼:** Empagliflozin, Dapagliflozin ë“±.\n- **Role:** ìµœê·¼ ê°€ì´ë“œë¼ì¸ì—ì„œ **CKD ì§„í–‰ì„ ëŠ¦ì¶”ëŠ” íš¨ê³¼**ê°€ ì…ì¦ë˜ì–´, ACEi/ARBì™€ í•¨ê»˜ ì‹ ì¥ ë³´í˜¸ì˜ í•µì‹¬ ì¶•ìœ¼ë¡œ ë¶€ìƒí–ˆìŠµë‹ˆë‹¤.\n    - íŠ¹íˆ eGFRì´ ë–¨ì–´ì ¸ ìˆëŠ” í™˜ìì—ê²Œë„ ì‹ ì¥ ë³´í˜¸ íš¨ê³¼(Renoprotective)ê°€ ê°•ë ¥í•©ë‹ˆë‹¤.\n---\n## ğŸ’¡ Clinical Pearl (ì‹œí—˜ì— ë‚˜ì˜¤ëŠ” í¬ì¸íŠ¸)\n- **Scenario:** í˜ˆì•• 120/80ì¸ ë‹¹ë‡¨ í™˜ìì˜ ì†Œë³€ ê²€ì‚¬ì—ì„œ UACRì´ 45 mg/gì´ ë‚˜ì™”ë‹¤. ì¡°ì¹˜ëŠ”?\n    - **ì •ë‹µ:** **Lisinopril (ACEi) ì‹œì‘.** (í˜ˆì••ì´ ì •ìƒì´ë¼ë„ ë‹¨ë°±ë‡¨ê°€ ìˆìœ¼ë©´ ì”ë‹ˆë‹¤.)\n- **Contraindication:** ë§Œì•½ í™˜ìê°€ ì„ì‹  ê³„íšì´ ìˆê±°ë‚˜ ì„ì‹  ì¤‘ì´ë¼ë©´?\n    - ACEi/ARBëŠ” ê¸ˆê¸°ì…ë‹ˆë‹¤.\n---\n## 7. Metabolic syndrome\n- 5ê°€ì§€ì¤‘ 3ê°€ì§€ì´ìƒ\n1. **Abdominal Obesity (ë³µë¶€ ë¹„ë§Œ):**\n    - ê°€ì¥ ì¤‘ìš”í•œ ì§€í‘œì…ë‹ˆë‹¤. ë‚´ì¥ ì§€ë°©(Visceral fat)ì´ ì¸ìŠë¦° ì €í•­ì„±ì˜ í•µì‹¬ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.\n    - â™‚ï¸ **Men:** > 40 inches\n    - â™€ï¸ **Women:** > 35 inches\n2. **Hypertriglyceridemia (ê³ ì¤‘ì„±ì§€ë°©):**\n    - **> 150 mg/dL**. (í˜¹ì€ ì•½ë¬¼ ë³µìš© ì¤‘).\n3. **Low HDL (ë‚®ì€ HDL):**\n    - â™‚ï¸ **Men:** < 40 mg/dL\n    - â™€ï¸ **Women:** < 50 mg/dL\n4. **Hypertension (ê³ í˜ˆì••):**\n    - **> 130 / 85 mmHg**. (ì¼ë°˜ì ì¸ ê³ í˜ˆì•• ì§„ë‹¨ ê¸°ì¤€ì¸ 130/80ê³¼ ë¯¸ì„¸í•˜ê²Œ ë‹¤ë¥´ë‹ˆ ì£¼ì˜! ìˆ˜ì¶•ê¸° 130, ì´ì™„ê¸° 85).\n5. **Hyperglycemia (ê³ í˜ˆë‹¹):**\n    - **Fasting Glucose > 100 mg/dL**. (ë‹¹ë‡¨ë³‘ ì§„ë‹¨ ê¸°ì¤€ì¸ 126ë³´ë‹¤ ë‚®ìŠµë‹ˆë‹¤. ì¦‰, **Pre-diabetes** ë‹¨ê³„ë¶€í„° í¬í•¨ë©ë‹ˆë‹¤).\n- Why do we care? (ì„ìƒì  ì˜ì˜) ğŸš‘\n    - d/t insulin resistance\n    - **Cardiovascular Risk:** ì‹¬í˜ˆê´€ ì§ˆí™˜ ë°œìƒ ìœ„í—˜ì´ 2ë°° ì´ìƒ ì¦ê°€í•©ë‹ˆë‹¤.\n    - **Type 2 Diabetes:** ë‹¹ë‡¨ë³‘ ë°œìƒ ìœ„í—˜ì´ 5ë°° ì´ìƒ ì¦ê°€í•©ë‹ˆë‹¤.\n    - **NASH (Non-alcoholic Steatohepatitis):** ë¹„ì•Œì½”ì˜¬ì„± ì§€ë°©ê°„ì—¼ê³¼ ë§¤ìš° ê°•ë ¥í•˜ê²Œ ì—°ê´€ë˜ì–´ ìˆìŠµë‹ˆë‹¤. (ALT > AST íŒ¨í„´).\n## 8. Hypoglycemia (ì €í˜ˆë‹¹) ğŸ“‰\n### 1. Definition & Whipple's Triad","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-141","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"- í˜ˆë‹¹ **< 70 mg/dL**.\n- **Whipple's Triad:**\n    1. ì €í˜ˆë‹¹ ì¦ìƒ (Sweating, tremor, confusion).\n    2. ì‹¤ì œ ë‚®ì€ í˜ˆë‹¹ ìˆ˜ì¹˜.\n    3. í¬ë„ë‹¹ íˆ¬ì—¬ í›„ ì¦ìƒ í˜¸ì „.\n- symptoms\n    - adrenergic : epinephrine, norepinephrine ì¦ê°€. ë¶ˆì•ˆ, ê¸´ì¥, ë•€\n    - neuroglycopenic: ë‡Œê°€ ë‹¹ì´ ì—†ì–´ì„œ ë‚˜íƒ€ë‚˜ëŠ” ì¦ìƒ.\n### 2. Treatment\n- **Awake:** ì£¼ìŠ¤ë‚˜ ì‚¬íƒ• ë“± ë¹ ë¥¸ íƒ„ìˆ˜í™”ë¬¼ ì„­ì·¨ (\"Rule of 15\").\n- **Unconscious (IV access O):** **IV Dextrose (D50)**. (ê°€ì¥ í™•ì‹¤í•¨).\n- **Unconscious (IV access X):** **IM Glucagon** (ê·¼ìœ¡ ì£¼ì‚¬).\n### 3. â˜… Diagnostic Workup (The Detective Work) ğŸ•µï¸â€â™‚ï¸\në‹¹ë‡¨ê°€ ì—†ëŠ” í™˜ìê°€ ì €í˜ˆë‹¹ìœ¼ë¡œ ì™”ì„ ë•Œ, ì›ì¸(ì¸ìŠë¦°ì¢… vs ì™¸ë¶€ ì£¼ì… vs ì•½ë¬¼)ì„ ê°ë³„í•˜ëŠ” ì•Œê³ ë¦¬ì¦˜ì…ë‹ˆë‹¤.\n| **Condition** | **Insulin** | **C-Peptide â˜…** | **Pro-insulin** | **Sulfonylurea Screen** |\n| --- | --- | --- | --- | --- |\n| **Exogenous Insulin** (ì£¼ì‚¬ íˆ¬ì—¬) | â¬†ï¸ High | **â¬‡ï¸ Low** | â¬‡ï¸ Low | (-) |\n| **Insulinoma** (ì¢…ì–‘) | â¬†ï¸ High | **â¬†ï¸ High** | â¬†ï¸ High | (-) |\n| **Sulfonylurea Abuse** (ì•½ë¬¼ ë³µìš©) | â¬†ï¸ High | **â¬†ï¸ High** | Normal | **(+) Positive** |\n## âš¡ Rapid Fire Recap (Must-Know Summary)\nì˜¤ë””ì˜¤ ë§ˆì§€ë§‰ì— ì •ë¦¬ëœ, **Step 2 ì‹œí—˜ì¥ì— ë“¤ì–´ê°€ê¸° ì „ ë°˜ë“œì‹œ ê¸°ì–µí•´ì•¼ í•  ë‚´ìš©**ì…ë‹ˆë‹¤.\n1. **DKA/HHS 1ìˆœìœ„ ì¹˜ë£Œ:** **Fluids (ìˆ˜ì•¡)**ì´ ë¨¼ì €ë‹¤! (1-2L Normal Saline).\n2. **Insulin ì „ K+ í™•ì¸:** K < 3.3ì´ë©´ **ì¸ìŠë¦° ì£¼ì§€ ë§ˆë¼(Hold)**. í™˜ì ì£½ëŠ”ë‹¤. 3.3 ë„˜ìœ¼ë©´ ì£¼ë©´ì„œ ì¸ìŠë¦° ì¤€ë‹¤. 5.2 ë„˜ìœ¼ë©´ ì¤€ë‹¤.\n3. **Metformin:** ì‹ ì¥ ê¸°ëŠ¥ í™•ì¸ (**GFR < 30 ê¸ˆê¸°**, Lactic Acidosis ìœ„í—˜).\n4. **Sulfonylureas:** ì €í˜ˆë‹¹ê³¼ ì²´ì¤‘ ì¦ê°€ì˜ ì£¼ë²”.\n5. **TZDs:** ì‹¬ë¶€ì „(CHF) í™˜ìì—ê²Œ **ê¸ˆê¸°**. (ë¶€ì¢… ìœ ë°œ).\n6. **SGLT-2 Inhibitors:** ì†Œë³€ìœ¼ë¡œ ë‹¹ ë°°ì¶œ. **UTI/Yeast infection** ì£¼ì˜. **Euglycemic DKA** ê°€ëŠ¥ì„± ì—¼ë‘.\n7. ì‹¬í˜ˆê´€ê³„, ì½©íŒ¥, ì‹¬ë¶€ì „ ìˆìœ¼ë©´ metformin ë‹¤ìŒë‹¨ê³„ë¡œ SGLT-2 inh.\n8. **Microalbuminuria:** 30~300 êµ¬ê°„ì—ì„œ ë°œê²¬ë˜ë©´ **ACEi/ARB** ì‹œì‘. (Efferent arteriole í™•ì¥).\n9. **Hypoglycemia Workup:** C-peptideë¥¼ í™•ì¸í•´ì„œ **Insulinoma(High)**ì™€ **ì™¸ë¶€ ì£¼ì‚¬(Low)**ë¥¼ êµ¬ë³„í•˜ë¼.\n---\n# ğŸ¥ Deep Dive: USMLE Step 2ë¥¼ ìœ„í•œ Adrenal Pathology (ë¶€ì‹  ë³‘ë¦¬í•™)\n## 1. Introduction: Taming the Beast ğŸ¦\n- **Goal:** USMLE Step 2 ë° ì‹¤ì œ ì„ìƒì„ ìœ„í•œ Mental Framework êµ¬ì¶•.\n- **í•µì‹¬ í¬ì¸íŠ¸:** ë‹¨ìˆœ ì•”ê¸°ë¥¼ ë„˜ì–´, **\"Next Best Step\"** (ë‹¤ìŒ ë‹¨ê³„ëŠ” ë¬´ì—‡ì¸ê°€?)ì„ ì´í•´í•˜ëŠ” ê²ƒì´ ëª©í‘œ.\n- **Adrenal Gland (ë¶€ì‹ ):** ì•½ 4gì˜ ì‘ì€ ê¸°ê´€ì´ì§€ë§Œ, Salt, Sugar, Blood Pressure, Stress ë°˜ì‘ì„ ì¡°ì ˆí•˜ëŠ” High-stakes organ.\n- **ê¸°ë³¸ ìƒë¦¬í•™ Mnemonic:**\n    - ğŸ§‚ **Salt** (Mineralocorticoids/Aldosterone)\n    - ğŸ­ **Sugar** (Glucocorticoids/Cortisol)\n    - ğŸ’ **Sex** (Androgens)\n    - ğŸš€ **Speed** (Catecholamines)\n- **ë¶„ë¥˜ (Categories):**\n    1. **Adrenal Excess** (ê³¼ë‹¤) -> Functional masses.\n    2. **Adrenal Masses** (íŠ¹íˆ Pheochromocytoma).\n    3. **Adrenal Insufficiency** (ë¶€ì¡±).\n---\n## 2. Adrenal Excess: The Functional Masses ğŸ“ˆ\n**ì„ìƒ ì–‘ìƒ (Clinical Presentation):** ì „ì‹  ì¦ìƒ(ì¡°ì ˆë˜ì§€ ì•ŠëŠ” HTN, ì²´í˜• ë³€í™” ë“±) ë˜ëŠ” **Incidentaloma**(CT ë“±ì—ì„œ ìš°ì—°íˆ ë°œê²¬ëœ ì¢…ì–‘)ë¡œ ë‚´ì›.\n**Incidentaloma ë°œê²¬ ì‹œ ì „ëµ:**\n- ì¦‰ì‹œ ë‘ ê°€ì§€ ì§ˆë¬¸ì„ ë˜ì ¸ì•¼ í•¨:\n    1. Is it cancer? (ì•”ì¸ê°€?)\n    2. Is it functional? (í˜¸ë¥´ëª¬ì„ ë¶„ë¹„í•˜ëŠ”ê°€?)\n- **The Golden Rule:** â˜… **Biochemistry before Biopsy.** (ìƒê²€ ì „ ìƒí™”í•™ ê²€ì‚¬ í•„ìˆ˜)\n    - *ì£¼ì˜:* ìƒí™”í•™ì  í™•ì¸ ì—†ì´ Pheochromocytomaë¥¼ ìƒê²€(Biopsy)í•˜ë©´, Adrenalineì´ ëŒ€ëŸ‰ ë°©ì¶œë˜ì–´ Hypertensive Crisisë¡œ í™˜ìê°€ ì‚¬ë§í•  ìˆ˜ ìˆìŒ.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-161","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","mnemonic"]}
{"chunk_type":"transcript_chunk","text":"### A. ğŸ§‚ Salt: Primary Hyperaldosteronism (Conn Syndrome)\n- **Classic Vignette:** 3ê°€ì§€ ì´ìƒì˜ ì•½ë¬¼(Diuretic í¬í•¨)ì—ë„ ì¡°ì ˆë˜ì§€ ì•ŠëŠ” **Resistant Hypertension** + **Hypokalemia** (ê·¼ìœ¡ ê²½ë ¨, ìœ„ì•½ê°).\n- **í•µì‹¬ ê°œë…: Aldosterone Escape**\n    - ë†’ì€ Aldosteroneì€ Na+ ì¬í¡ìˆ˜ & K+ ë°°ì¶œì„ ìœ ë°œí•¨.\n    - ì´ˆê¸°ì—ëŠ” ë¬¼ì´ Na+ë¥¼ ë”°ë¼ê°€ Volume expansionì´ ì¼ì–´ë‚¨.\n    - **Why no edema? (ì™œ ë¶€ì¢…ì´ ì—†ëŠ”ê°€?):** ì‹¬ë°©ì´ ëŠ˜ì–´ë‚˜ë©´ì„œ **ANP**ê°€ ë¶„ë¹„ë˜ì–´ ì‹ ì¥ì—ì„œ ê°•ì œë¡œ Sodium/Waterë¥¼ ë°°ì¶œì‹œí‚´ (Pressure Natriuresis).\n    - *ê²°ê³¼:* ê³ í˜ˆì••ì€ ìˆì§€ë§Œ ë¶€ì¢…(Edema)ì€ ì—†ìŒ. (Edemaê°€ ìˆë‹¤ë©´ Heart Failureë‚˜ Cirrhosisë¥¼ ì˜ì‹¬).\n- **Labs:** **Hypokalemia** + **Metabolic Alkalosis**. (HypokalemiaëŠ” Diuretic ì‚¬ìš© ì „ê¹Œì§€ëŠ” ì •ìƒì¼ ìˆ˜ë„ ìˆìŒ). í™˜ìê°€ normal-normallow potassium levelë¡œ ë‚´ì›í•  ìˆ˜ ìˆìœ¼ë‚˜, ì´ë‡¨ì œì— ê³¼í•˜ê²Œ hypokalemiaë°˜ì‘í•¨.\n- **Diagnostic Algorithm (ì§„ë‹¨ ìˆœì„œ):**\n    1. **Screen:** Aldosterone/Renin Ratio.\n        - High Aldo + Low Renin (Suppressed).\n        - **Positive Screen:** Ratio > 20 (ë‹¨, absolute Aldo > 15 ng/dL).\n    2. **Confirm:** Salt Loading Test.\n        - ì†Œê¸ˆ ë¶€í•˜(ì‹ì‚¬ ë˜ëŠ” IV Saline)ë¥¼ ì£¼ì—ˆì„ ë•Œ Aldosteroneì´ ì–µì œë˜ì§€ ì•Šìœ¼ë©´ ì–‘ì„±.\n    3. **Localize:** CT Scan.\n        - *í•¨ì •:* CTì—ì„œ Massê°€ ë³´ì¸ë‹¤ê³  ë¬´ì¡°ê±´ ê·¸ìª½ì´ ì›ì¸ì´ ì•„ë‹˜ (ë¹„ê¸°ëŠ¥ì„± ì¢…ì–‘ì¼ ìˆ˜ ìˆìŒ).\n        - 40ì„¸ ë„˜ëŠ”í™˜ìì—ì„œëŠ” non functioning incidentalomaê°€ ë§ìŒ. ê·¸ëƒ¥ lumpê°€ ë³´ì¸ë‹¤ê³  ë—ëŠ”ë° ì‚¬ì‹¤ ì•„ë¬´ê²ƒë„ ì•„ë‹ˆì—ˆì„ ìˆ˜ ìˆìŒ. 40ì„¸ ë„˜ì—ˆìœ¼ë©´ ë©ì–´ë¦¬ìˆë‹¤ê³  ê·¸ëƒ¥ ë¬´ì§€ì„± ë–¼ê¸° ì•ˆë¨!\n    4. **Differentiate:** â˜… **Adrenal Venous Sampling (AVS).**\n        - ìˆ˜ìˆ  ì „ Gold Standard. ì–‘ìª½ ì •ë§¥ì—ì„œ í˜¸ë¥´ëª¬ì„ ì±„ì·¨í•˜ì—¬ **Unilateral Adenoma**ì¸ì§€ **Bilateral Hyperplasia**ì¸ì§€ êµ¬ë³„.\n- **Treatment:**\n    - **Unilateral Adenoma:** Surgical resection (ìˆ˜ìˆ ì  ì ˆì œ, ì™„ì¹˜ ê°€ëŠ¥).\n    - **Bilateral Hyperplasia:** **Mineralocorticoid Receptor Antagonists (MRAs)**ë¡œ ì•½ë¬¼ ì¹˜ë£Œ.\n        - *Spironolactone:* Androgen ìˆ˜ìš©ì²´ë„ ì°¨ë‹¨í•˜ì—¬ Gynecomastia, Libido ê°ì†Œ ë¶€ì‘ìš© ìˆìŒ.\n        - *Eplerenone:* ë¶€ì‘ìš©ì´ ì ì€ ëŒ€ì²´ ì•½ë¬¼.\n### B. ğŸ­ Sugar: Cushing Syndrome (Hypercortisolism)\n- **Presentation:** Central obesity, Moon facies, Buffalo hump, â˜… **Wide Purple Striae (>1cm)**, Easy bruising.\n    - *êµ¬ë³„ì :* **Proximal Muscle Weakness** (ê³„ë‹¨ ì˜¤ë¥´ê¸° í˜ë“¦, ë¨¸ë¦¬ ë¹—ê¸° í˜ë“¦) - ë‹¨ë°±ì§ˆ ë¶„í•´(Catabolic effect) ë•Œë¬¸.\n- **Diagnosis (The 2 out of 3 Rule):** ë‹¤ìŒ ì„ ë³„ ê²€ì‚¬ ì¤‘ 2ê°€ì§€ê°€ ì–‘ì„±ì´ì–´ì•¼ í™•ì§„.\n    1. **24-hour Urinary Free Cortisol.**\n    2. **Late Night Salivary Cortisol:** ì¼ì£¼ê¸° ë¦¬ë“¬(Diurnal rhythm) ì†Œì‹¤ í™•ì¸ (ìì •ì— Cortisolì´ ë†’ìœ¼ë©´ ë¹„ì •ìƒ).\n    3. **Low-dose Dexamethasone Suppression Test:** ì •ìƒì´ë¼ë©´ ACTHê°€ ì–µì œë˜ê³  ë”°ë¼ì„œ, ë‹¤ìŒë‚  ì•„ì¹¨ ì½”í‹°ì†”ë„ ì–µì œë˜ì–´ì•¼ í•˜ë‚˜, Cushingì€ ì•„ì¹¨ ì½”í‹°ì†”ì´ ì–µì œë˜ì§€ ì•ŠìŒ.\n- **ì›ì¸ ê°ë³„ (ACTH Level):**\n    - **Low ACTH:** Primary Adrenal problem (Tumor).\n        - low DHEAë‘ ë™ë°˜ë˜ëŠ” ê²½ìš° ë§ìŒ (DHEAë„ ACTHì˜ ìê·¹ì„ ë°›ê¸° ë•Œë¬¸)\n        - iatrogenic ë¨¼ì € ë°˜ë“œì‹œ rule out â˜… â˜…  Low ACTH, low DHEA\n    - **High ACTH:** ACTH-dependent (Pituitary or Ectopic).\n- **High-Dose Dexamethasone Suppression Test (High ACTHì¸ ê²½ìš°):**\n    - **Cushing Disease (Pituitary Adenoma):** ì–´ëŠ ì •ë„ Feedbackì´ ë‚¨ì•„ ìˆì–´ High-doseì—ì„œ ì–µì œë¨ (>50%).\n    - **Ectopic ACTH (ì˜ˆ: Small Cell Lung Cancer):** ììœ¨ì  ë¶„ë¹„. High-doseì—ì„œë„ **ì–µì œë˜ì§€ ì•ŠìŒ**. hyperpigmentation â˜… (addisonì²˜ëŸ¼)\n- **Ectopic (Lung Cancer) ì„ìƒ íŒíŠ¸:**\n    - ê¸‰ê²©í•œ ì§„í–‰, ë¹„ë§Œë³´ë‹¤ëŠ” Cachexia(ë©”ë§ˆë¦„), ì‹¬í•œ Hyperpigmentation, ë§¤ìš° ë†’ì€ ACTH ìˆ˜ì¹˜.\n### C. ğŸš€ Speed: Pheochromocytoma (Medullary Tumor)\n- **Chromaffin Cells ì¢…ì–‘:** Catecholamines (Epi, Norepi, Dopamine) ë¶„ë¹„.\n- **Classic Triad (3 P's):**\n    1. **P**aroxysmal Headache (ë°œì‘ì  ë‘í†µ).\n    2. **P**alpitations/Tachycardia.\n    3. **P**erspiration (ë°œí•œ).\n    - *í•µì‹¬:* ì¦ìƒì´ **Paroxysmal** (ì™”ë‹¤ ê°”ë‹¤ í•¨) í•˜ë‹¤ëŠ” ê²ƒ.\n- **Diagnosis:**\n    - Screen: Plasma Free Metanephrines (ë¯¼ê°ë„ ë†’ìŒ).\n    - Confirm: 24-hour Urine Metanephrines.\n- **ê°ë³„ í¬ì¸íŠ¸:**\n    - **Thyroid Storm:** ê³ ì—´(Hyperpyrexia) ë™ë°˜.\n    - **Pheo:** ë•€ì€ ë‚˜ì§€ë§Œ **FeverëŠ” ê±°ì˜ ì—†ìŒ**.\n- **Triggers:** ìˆ˜ìˆ /ë§ˆì·¨ ìœ ë„(Induction), ë³µì•• ìƒìŠ¹ ë“±.\n- **Treatment Rule:** â˜… **A before B**\n    - **Alpha-blocker FIRST** (Phenoxybenzamine) - í˜ˆê´€ ì´ì™„.\n    - **Beta-blocker SECOND** - ì‹¬ë°•ìˆ˜ ì¡°ì ˆ.\n    - *ì´ìœ :* Beta-blockerë¥¼ ë¨¼ì € ì“°ë©´, í˜ˆê´€ ìˆ˜ì¶• ì‘ìš©(Alpha)ë§Œ ë‚¨ì•„ **Unopposed Alpha Stimulation**ìœ¼ë¡œ í˜ˆì••ì´ í­ë“±í•˜ì—¬ ì‚¬ë§ ê°€ëŠ¥.\n---\n## 3. Adrenal Insufficiency (The \"Too Little\") ğŸ“‰\n**ë¶„ë¥˜:** Primary (ë¶€ì‹  ìì²´ íŒŒê´´), Secondary (ë‡Œí•˜ìˆ˜ì²´), Tertiary (ì‹œìƒí•˜ë¶€).\n### A. Primary Adrenal Insufficiency (Addison's Disease)\n- **Pathology:** Adrenal cortexì˜ íŒŒê´´. **Cortisol**, **Aldosterone**, **Androgens** ëª¨ë‘ ê²°í•.\n- **Etiology (ì›ì¸):**\n    - *ì„ ì§„êµ­:* Autoimmune Adrenalitis.\n    - *ê°œë°œë„ìƒêµ­/ì „ì„¸ê³„:* **Tuberculosis (TB)** (CTìƒ ì„íšŒí™”ëœ ë¶€ì‹ ).\n- **Symptoms & Labs:**\n    - **Hyperpigmentation:** ë†’ì€ ACTH (POMC -> MSH ìê·¹) ë•Œë¬¸. ì†ë°”ë‹¥ ì£¼ë¦„, êµ¬ê°• ì ë§‰ ì°©ìƒ‰.\n    - **Salt Craving:** Aldosterone ê²°í• ë•Œë¬¸.\n    - **Electrolytes:** â˜… **Hyponatremia + Hyperkalemia** (Na ë²„ë¦¬ê³  K ì €ì¥).\n    - **Acidosis:** Non-anion gap metabolic acidosis.\n    - **Eosinophilia:** Cortisolì´ ì—†ì–´ì„œ Eosinophilì´ ì¦ê°€.\n    - **ì—¬ì„±:** ì²´ëª¨(Axillary/pubic hair) ì†Œì‹¤ ë° ì„±ìš• ê°ì†Œ (Adrenal androgen ê²°í•).\n    - SIADH. ADH ì¦ê°€.\n### B. Secondary/Tertiary Adrenal Insufficiency\n- **Etiology:** ë§Œì„± ìŠ¤í…Œë¡œì´ë“œ ì‚¬ìš© í›„ ì¤‘ë‹¨ (ê°€ì¥ í”í•œ ì˜ì¸ì„± ì›ì¸).\n- **í•µì‹¬ ì°¨ì´ì :** **Aldosteroneì€ ì •ìƒ (INTACT)** (RAASì— ì˜í•´ ì¡°ì ˆë˜ë¯€ë¡œ).\n    - ë”°ë¼ì„œ Hyperkalemiaë‚˜ Salt cravingì´ ì—†ìŒ.\n    - **No Hyperpigmentation** (ACTHê°€ ë‚®ìœ¼ë¯€ë¡œ).\n    - ì¦ìƒì´ ëª¨í˜¸í•¨ (í”¼ë¡œ, ìœ„ì•½ê°, ì˜¤ì‹¬).\n### C. Diagnostic Algorithm\n1. basal cortisol, basal ACTH ì¸¡ì •\n    1. cortisolì´ 3ë°‘ìœ¼ë¡œ ë‚®ìœ¼ë©´ í™•ì§„\n    2. cortisolì´ 3-8ë¡œ ì• ë§¤í•˜ë©´?\n2. ACTH (cosynotropin) stimulationê²€ì‚¬: cortisol ë°˜ì‘ì—¬ë¶€ë¡œ AI ìì²´ë¥¼ í™•ì§„\n    1. ì •ìƒ: ACTHíˆ¬ì—¬ í›„ ì½”í‹°ì†”ì´ ëœ¬ë‹¤.\n    2. ë¹„ì •ìƒ: ACTHíˆ¬ì—¬ í›„ì—ë„ cortisolì´ ë‚®ë‹¤. ì˜¤ë¡œì§€ AI í™•ì§„ì´ë©° êµ¬ì²´ì ì¸ AI ìœ í˜• ë¶„ë¥˜ì— ì“°ì§€ ì•ŠìŒ! â˜… â˜…\n    note: primary, secondary, tertiary ëª¨ë‘ ACTH ìê·¹ê²€ì‚¬ì— ì½”í‹°ì†”ì´ ë°˜ì‘ì•ˆí•œë‹¤. í‘œë©´ì ìœ¼ë¡œ adrenal glandì— ë¬¸ì œ ì—†ëŠ” secondary, tertiary AIë„ ACTHìê·¹ ê²€ì‚¬ì— ë°˜ì‘í•˜ì§€ ì•ŠëŠ”ë‹¤!\n3. ACTH high (primary AI) vs ACTH low (secondary, tertiary AI): ACTHìˆ«ìë¡œ AI ìœ í˜•ì„ ë¶„ë¥˜í•œë‹¤.\n### D. ğŸš¨ Adrenal Crisis (Acute Insufficiency)\n- **Scenario:** ë¶€ì‹  ê¸°ëŠ¥ì´ ì €í•˜ëœ í™˜ìê°€ í° ìŠ¤íŠ¸ë ˆìŠ¤(ìˆ˜ìˆ , ê°ì—¼, ì™¸ìƒ)ë¥¼ ë°›ê±°ë‚˜ ìŠ¤í…Œë¡œì´ë“œë¥¼ ê°‘ìê¸° ì¤‘ë‹¨í–ˆì„ ë•Œ.\n- **Precipitants (ìœ ë°œ ìš”ì¸):**\n    - **Waterhouse-Friderichsen Syndrome:** Meningococcemia (*Neisseria meningitidis*)ì— ì˜í•œ ì–‘ì¸¡ ë¶€ì‹  ì¶œí˜ˆ.\n    - **Etomidate:** ë§ˆì·¨ ìœ ë„ì œ. 11-beta-hydroxylaseë¥¼ ì–µì œí•˜ì—¬ íŒ¨í˜ˆì¦ í™˜ìì—ì„œ ìœ„ê¸° ìœ ë°œ ê°€ëŠ¥.\n- **Presentation:**\n    - **Refractory Shock:** ìˆ˜ì•¡ê³¼ ìŠ¹ì••ì œ(Pressors)ì— ë°˜ì‘í•˜ì§€ ì•ŠëŠ” ì‡¼í¬.\n    - Acute abdomenê³¼ ìœ ì‚¬í•œ ì‹¬í•œ ë³µí†µ, êµ¬í† .\n    - Hypotension, Hypoglycemia.\n- **Management (ì¹˜ë£Œ):**\n    - â˜… **ê²€ì‚¬ ê²°ê³¼ë¥¼ ê¸°ë‹¤ë¦¬ì§€ ë§ ê²ƒ (Do NOT wait for labs).**\n    - **ì¦‰ê°ì ì¸ ì²˜ì¹˜:**\n        1. **IV Hydrocortisone** (Stress dose - Glucocorticoid & Mineralocorticoid íš¨ê³¼ ëª¨ë‘ ìˆìŒ).\n        2. Aggressive IV Fluids (Normal Saline).\n---","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-181","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis","treatment","pathophysiology","tree"]}
{"chunk_type":"recap_summary","text":"## 4. Rapid Fire Recap ğŸ”¥ (ì¡±ë³´ ì •ë¦¬)\n1. **Conn Syndrome ì§„ë‹¨ (Rule of 2):**\n    - Screen: Aldo/Renin Ratio > 20.\n    - Confirm: Salt Loading Test (ì–µì œ ì‹¤íŒ¨).\n2. **Cushing Screening (2 out of 3 Rule):**\n    - ë‹¤ìŒ ì¤‘ 2ê°œ ì–‘ì„± í•„ìš”: 24hr Urine, Late Night Saliva, Low-Dose Dex.\n3. **The Great Electrolyte Split (ì „í•´ì§ˆ ì°¨ì´):**\n    - **Conn's:** High BP, Low K+, High Na+.\n    - **Addison's:** Low BP, High K+, Low Na+.\n4. **Pigmentation Clue (ìƒ‰ì†Œì¹¨ì°© íŒíŠ¸):**\n    - Hyperpigmentation = **High ACTH** (Primary AI ë˜ëŠ” Ectopic Cushing's).\n    - No Pigmentation = Secondary AI ë˜ëŠ” Pituitary Cushing's.\n5. **Refractory Signs (ì¹˜ë£Œ ë¶ˆì‘ ì§•í›„):**\n    - 3ê°€ì§€ ì•½ì œì—ë„ ì•ˆ ë“£ëŠ” HTN = **Conn Syndrome.**\n    - ìˆ˜ì•¡/ìŠ¹ì••ì œì— ì•ˆ ë“£ëŠ” Hypotension = **Adrenal Crisis.**\n6. **Iatrogenic Warning (ì˜ì¸ì„± ê²½ê³ ):**\n    - ì˜ì‚¬ê°€ ë§Œë“œëŠ” ê°€ì¥ í”í•œ ë¶€ì‹  ë¬¸ì œ = ë§Œì„± ìŠ¤í…Œë¡œì´ë“œ ì‚¬ìš©ìœ¼ë¡œ ì¸í•œ **Secondary Adrenal Insufficiency**.\n    - *ê¸°ì–µí•  ê²ƒ:* ì–µì œëœ ë¶€ì‹ ì€ ìˆ˜ìˆ /ì§ˆë³‘ ì‹œ ìŠ¤íŠ¸ë ˆìŠ¤ ë°˜ì‘ì„ ëª»í•˜ë¯€ë¡œ ë°˜ë“œì‹œ **Stress-dose Steroids**ë¥¼ ì¤˜ì•¼ í•¨!\n---\n# ğŸ§ Deep Dive: Thyroid Nodules, Adrenal Tumors, & MEN Syndromes\n## 1. Introduction: From Physiology to Pathology\n- ì´ë²ˆ ì„¸ì…˜ì˜ ë¶„ìœ„ê¸°ëŠ” ì´ì „(Physiology)ê³¼ëŠ” ì™„ì „íˆ ë‹¤ë¦…ë‹ˆë‹¤. \"How it works\"ì—ì„œ **\"What happens when things grow\"**ë¡œ ì „í™˜ë©ë‹ˆë‹¤.\n- ì£¼ìš” í…Œë§ˆ: **Mass Effects** (ì¢…ì–‘, ê²°ì ˆì´ ì»¤ì§€ë©´ì„œ ìƒê¸°ëŠ” ë¬¸ì œë“¤).\n- ë‹¤ë£¨ëŠ” ë‚´ìš©ì´ ë§ˆì¹˜ \"ê³µí¬ ì˜í™” ìºìŠ¤íŒ…(Horror movie cast)\"ì²˜ëŸ¼ ë“¤ë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤ (ì˜ˆ: Neuroma, Thyroid storm ë“±).\n- **ëª©í‘œ:** ë‹¨ìˆœí•œ ì§ˆë³‘ ë‚˜ì—´ì´ ì•„ë‹ˆë¼, **Framework(ì‚¬ê³ ì˜ í‹€)**ë¥¼ ë§Œë“œëŠ” ê²ƒ. ì–¸ì œ ìŠ¤ìº”í•˜ê³ , ì–¸ì œ ìƒê²€(Biopsy)í•˜ê³ , ì–¸ì œ ì™¸ê³¼ì˜ë¥¼ ë¶€ë¥¼ì§€ ê²°ì •í•˜ëŠ” **Algorithm**ì„ ìµíˆëŠ” ê²ƒì´ í•µì‹¬ì…ë‹ˆë‹¤.\n---\n## 2. Thyroid Nodules: The Algorithm (ê°‘ìƒì„  ê²°ì ˆ ì ‘ê·¼ë²•)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-199","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","recap","diagnosis","treatment","tree"]}
{"chunk_type":"transcript_chunk","text":"ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤: í™˜ìê°€ ëª©ì— ë©ì–´ë¦¬(Lump)ê°€ ë§Œì ¸ì ¸ì„œ ë‚´ì›í–ˆìŠµë‹ˆë‹¤. ë³¸ëŠ¥ì ìœ¼ë¡œëŠ” ë°”ë¡œ ë°”ëŠ˜ì„ ì°”ëŸ¬ í™•ì¸í•˜ê³  ì‹¶ì§€ë§Œ, **Endocrinologyì—ì„œëŠ” ê·¸ê²ƒì´ í‹€ë¦° ì ‘ê·¼ì…ë‹ˆë‹¤.**\n### â˜… Step 1: The Gatekeeper - TSH Level\nê°€ì¥ ë¨¼ì € í™•ì¸í•´ì•¼ í•  ê²ƒì€ **TSH ìˆ˜ì¹˜**ì…ë‹ˆë‹¤.\n- **TSHê°€ ë‚®ë‹¤ (Low TSH):**\n    - ë‡Œê°€ ê°‘ìƒì„  ìê·¹ì„ ë©ˆì·„ë‹¤ëŠ” ëœ»ì…ë‹ˆë‹¤.\n    - ì¦‰, ê²°ì ˆ(Nodule)ì´ ìŠ¤ìŠ¤ë¡œ í˜¸ë¥´ëª¬ì„ ë¿œì–´ë‚´ê³  ìˆë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. -> **\"Hot\" Nodule** ğŸ”¥\n    - **â˜… Key Insight:** \"Hot nodule\"ì€ ê±°ì˜ ì ˆëŒ€ì ìœ¼ë¡œ **ì•…ì„±(Malignant)ì´ ì•„ë‹™ë‹ˆë‹¤.** (Hyper-functioning nodule is rarely cancer).\n    - **Action:** **Radioactive Iodine Scintigraphy (í•µì˜í•™ ìŠ¤ìº”)**ì„ ì‹œí–‰í•©ë‹ˆë‹¤. ìŠ¤ìº”ìƒ í¬ë¦¬ìŠ¤ë§ˆìŠ¤ íŠ¸ë¦¬ì²˜ëŸ¼ ë°ê²Œ ë¹›ë‚˜ë©´(Light up), ì•” ê±±ì •ì€ ì ‘ì–´ë‘ê³  **Hyperthyroidism(ê°‘ìƒì„  í•­ì§„ì¦)** ì¹˜ë£Œë¥¼ í•˜ë©´ ë©ë‹ˆë‹¤. **Biopsy í•˜ì§€ ë§ˆì„¸ìš”!**\n- **TSHê°€ ì •ìƒ í˜¹ì€ ë†’ë‹¤ (Normal/High TSH):**\n    - ê²°ì ˆì´ ê¸°ëŠ¥ì„ í•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ëœ»ì…ë‹ˆë‹¤. -> **\"Cold\" Nodule** â„ï¸\n    - ì´ ê²½ìš° ì•…ì„±ì˜ ê°€ëŠ¥ì„±ì´ ìˆìœ¼ë¯€ë¡œ í•´ë¶€í•™ì  êµ¬ì¡°ë¥¼ ë´ì•¼ í•©ë‹ˆë‹¤.\n    - **Action:** **Ultrasound (ì´ˆìŒíŒŒ)** ì‹œí–‰.\n### Step 2: Ultrasound Features (The Ugly Check)\nì´ˆìŒíŒŒì—ì„œ ë‹¨ìˆœíˆ í¬ê¸°ë§Œ ë³´ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ **\"Ugly Features\"**ë¥¼ ì°¾ìŠµë‹ˆë‹¤.\n- Microcalcifications (ë¯¸ì„¸ì„íšŒí™”)\n- Irregular borders (ë¶ˆê·œì¹™í•œ ê²½ê³„ - ì¹¨ë²”í•˜ëŠ” ëª¨ì–‘)\n- Increased vascularity (í˜ˆë¥˜ ì¦ê°€)\n### Step 3: FNA (Fine Needle Aspiration)\n- **ì–¸ì œ í•˜ëŠ”ê°€?:** TSHê°€ ì •ìƒ/ë†’ìŒ **AND** ì´ˆìŒíŒŒì—ì„œ \"Ugly\"í•˜ê±°ë‚˜ í¬ê¸°ê°€ í´ ë•Œ (>1cm).\n- ì´ë•Œ ë¹„ë¡œì†Œ ë°”ëŠ˜ë¡œ ì°”ëŸ¬ ì•”ì¸ì§€ í™•ì¸í•©ë‹ˆë‹¤.\n### Step 4: ìˆ˜ìˆ  (lobectomy vs total thyroidectomy)\n- ê¸°ì¤€ 1cm\n- total thyroidectomy í›„ serum thyroglobulinìœ¼ë¡œ ì¶”ì ê²€ì‚¬ ê°€ëŠ¥\n- Adjunctant therapy: Radioiodine ablation and/or suppressive doses of thyroid hormones.\n    - Suppressive doses of thyroid hormone: ì¬ë°œ ê°€ëŠ¥ì„±ì´ ìˆìœ¼ë©´ levothyroxineì„ ì¼ë¶€ëŸ¬ ë†’ê²Œ ì¤Œ â†’ TSHê°€ ë‚®ê²Œ ìœ ì§€ë˜ë„ë¡.\n---\n## 3. Pediatric Trap: Thyroglossal Duct Cyst ğŸ‘…\nì†Œì•„ê³¼ì—ì„œ ìì£¼ ë‚˜ì˜¤ëŠ” í•¨ì • ë¬¸ì œì…ë‹ˆë‹¤.\n- **ìœ„ì¹˜:** Midline neck mass (ëª© ì •ì¤‘ì•™).\n- **ë°œìƒí•™:** ê°‘ìƒì„ ì€ í˜€ ê¸°ì €ë¶€(Base of tongue)ì—ì„œ ì‹œì‘í•´ ëª© ì•„ë˜ë¡œ ë‚´ë ¤ì˜µë‹ˆë‹¤. ì´ ê²½ë¡œì— ë‚¨ì€ í”ì ì…ë‹ˆë‹¤.\n- **íŠ¹ì§•:** í˜€ë¥¼ ë‚´ë°€ê±°ë‚˜ ì¹¨ì„ ì‚¼í‚¤ë©´ ë©ì–´ë¦¬ê°€ **ìœ„ë¡œ ì›€ì§ì…ë‹ˆë‹¤ (Moves up)**.\n- **â˜… Critical Step before Surgery:**\n    - ë¬´í„±ëŒ€ê³  ì˜ë¼ë‚´ë©´ ì•ˆ ë©ë‹ˆë‹¤. ì´ ë‚­ì¢…ì´ **ì•„ì´ì˜ \"ìœ ì¼í•œ\" ê°‘ìƒì„  ì¡°ì§(Ectopic thyroid)**ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n    - í™•ì¸í•˜ì§€ ì•Šê³  ì œê±°í•˜ë©´ ì•„ì´ëŠ” í‰ìƒ **Hypothyroidism(ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦)**ì´ ë©ë‹ˆë‹¤.\n    - ìˆ˜ìˆ  ì „ ë°˜ë“œì‹œ **Ultrasound**ë‚˜ **Nuclear scan**ìœ¼ë¡œ ì •ìƒ ìœ„ì¹˜ì— ê°‘ìƒì„ ì´ ìˆëŠ”ì§€ í™•ì¸í•´ì•¼ í•©ë‹ˆë‹¤.\n---\n## 4. Thyroid Malignancies & Emergencies\n### A. Thyroid Lymphoma & Hashimoto's\n- **ì—°ê´€ì„±:** ë§Œì„±ì ì¸ ì—¼ì¦(Chronic inflammation)ì€ ì„¸í¬ ë³€ì´ì˜ ì˜¨ìƒì…ë‹ˆë‹¤. ì˜¤ë«ë™ì•ˆ **Hashimoto's thyroiditis**ë¥¼ ì•“ë˜ í™˜ìì—ê²Œì„œ ë°œìƒ ìœ„í—˜ì´ ë†’ìŠµë‹ˆë‹¤.\n- **ì¦ìƒ:**\n    - **Rapid growth:** ê°‘ìê¸° ëª©ì´ ë¹ ë¥´ê²Œ ë¶“ìŠµë‹ˆë‹¤.\n    - **Firm/Woody:** ë”±ë”±í•˜ê²Œ ë§Œì ¸ì§‘ë‹ˆë‹¤.\n    - **Compressive symptoms:** ëª©ì´ ì¡¸ë¦¬ëŠ” ëŠë‚Œ, ì‚¼í‚´ ê³¤ë€.\n- **â˜… Pemberton Sign:**\n    - í™˜ìì—ê²Œ ì–‘íŒ”ì„ ë¨¸ë¦¬ ìœ„ë¡œ ë“¤ê²Œ í•©ë‹ˆë‹¤ (\"Touchdown sign\").\n    - ê±°ëŒ€í•´ì§„ ê°‘ìƒì„ ì´ í‰ê³½ ì…êµ¬(Thoracic inlet)ë¥¼ ë§‰ì•„ ì •ë§¥ í™˜ë¥˜ë¥¼ ì°¨ë‹¨í•©ë‹ˆë‹¤.\n    - ê²°ê³¼: ì–¼êµ´ì´ ë¹¨ê°œì§€ê³ (Plethora), ì–´ì§€ëŸ¬ì›€ì„ ëŠë‚ë‹ˆë‹¤. -> **ì‘ê¸‰ ì˜ìƒ ì´¬ì˜ ë° ìˆ˜ìˆ  ê³ ë ¤.**\n### B. Thyroid Storm (ê°‘ìƒì„  í­í’) ğŸŒªï¸","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-209","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","treatment"]}
{"chunk_type":"transcript_chunk","text":"- ì§„ì •í•œ ë‚´ë¶„ë¹„ ì‘ê¸‰ ìƒí™© (Medical Emergency). Thyrotoxicosisê°€ ë ˆë²¨ 11ë¡œ ì¹˜ì†Ÿì€ ìƒíƒœ.\n- **Trigger:** ìˆ˜ìˆ , ì™¸ìƒ, ê°ì—¼, í˜¹ì€ ë¶„ë§Œ(Childbirth).\n- **ì¦ìƒ:**\n    - High Fever (ê³ ì—´)\n    - Massive Tachycardia (ì‹¬ë°•ìˆ˜ 140-160)\n    - Agitation, Delirium (í¥ë¶„, ì„¬ë§ - ë¯¸ì³ ë‚ ë›°ëŠ” ìƒíƒœ)\n| **êµ¬ë¶„** | **Thyroid Storm (ê°‘ìƒì„  í­í’)** | **Malignant Hyperthermia (ì•…ì„± ê³ ì—´ì¦)** |\n| --- | --- | --- |\n| **ê³µí†µì ** | ìˆ˜ìˆ  í›„ ë°œìƒ ê°€ëŠ¥, ê³ ì—´, ë¹ˆë§¥ | ìˆ˜ìˆ  í›„ ë°œìƒ ê°€ëŠ¥(ë§ˆì·¨ì œ), ê³ ì—´, ë¹ˆë§¥ |\n| **ì°¨ì´ì ** | **â˜… No Rigidity (ê²½ì§ ì—†ìŒ)**\n (ë–¨ë¦¼ì´ë‚˜ Lid lagì€ ìˆì„ ìˆ˜ ìˆìŒ) | **Rigidity (ì „ì‹  ê·¼ìœ¡ ê°•ì§)** |\n| **ì¹˜ë£Œ** | Cooling, Beta-blockers, Steroids | Dantrolene |\n---\n## 5. Adrenal Tumors: The Stress Glands\n### A. Pheochromocytoma (The Great Mimic)\n- ë¶€ì‹  ìˆ˜ì§ˆ(Medulla)ì˜ ì¢…ì–‘ìœ¼ë¡œ, **Catecholamine (Epinephrine/Norepinephrine)**ì„ ë¿œì–´ëƒ…ë‹ˆë‹¤.\n- **ì¦ìƒ: The Classic Triad + HTN**\n    1. **H**eadache (ë‘í†µ)\n    2. **S**weating (ë°œí•œ - í™˜ìê°€ ë•€ì— í ë»‘ ì –ìŒ)\n    3. **P**alpitations (ë‘ê·¼ê±°ë¦¼ - ì‹¬ì¥ì´ íŠ€ì–´ë‚˜ì˜¬ ê²ƒ ê°™ìŒ)\n    - ì´ ì¦ìƒë“¤ì´ **ë°œì‘ì (Paroxysmal/Spells)**ìœ¼ë¡œ ë‚˜íƒ€ë‚©ë‹ˆë‹¤.\n- **ì§„ë‹¨ (Dx):**\n    - ë‹¨ìˆœ ì•„ë“œë ˆë‚ ë¦° ìˆ˜ì¹˜ê°€ ì•„ë‹ˆë¼ **Metanephrines (ë¶„í•´ ì‚°ë¬¼)**ì„ í˜ˆì•¡(Plasma)ì´ë‚˜ ì†Œë³€(Urine)ì—ì„œ ì¸¡ì •í•©ë‹ˆë‹¤.\n    - **ì´ìœ :** ì•„ë“œë ˆë‚ ë¦°ì€ ê¸ˆë°© ì‚¬ë¼ì§€ì§€ë§Œ, MetanephrinesëŠ” ë°œì‘ ì‚¬ì´ì—ë„ ìˆ˜ì¹˜ê°€ ë†’ê²Œ ìœ ì§€ë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤ (More reliable).\n### B. Neuroblastoma (Pediatric) ğŸ‘¶\n- ì†Œì•„ì—ì„œ ê°€ì¥ í”í•œ ë‘ê°œê°• ì™¸ ê³ í˜• ì¢…ì–‘(Extracranial solid tumor).\n- **ê¸°ì›:** Neural Crest cells (ë¶€ì‹ ).\n- **íŠ¹ì§•:**\n    - **Irregular mass crosses midline:** ë³µë¶€ ë©ì–´ë¦¬ê°€ ì •ì¤‘ì„ (Midline)ì„ ë„˜ì–´ê°‘ë‹ˆë‹¤. (Wilms tumorëŠ” ì½©íŒ¥ ì¢…ì–‘ì´ë¼ ì•ˆ ë„˜ì–´ê°).\n    - **â˜… Opsoclonus-Myoclonus Syndrome:** \"Dancing eyes, Dancing feet.\" ì•„ì´ì˜ ëˆˆì´ ì œë©‹ëŒ€ë¡œ ì›€ì§ì´ê³  íŒ”ë‹¤ë¦¬ê°€ ì”°ë£©ê±°ë¦½ë‹ˆë‹¤.\n### C. Incidentaloma (ìš°ì—°íˆ ë°œê²¬ëœ ì¢…ì–‘)\n- CT ì°ë‹¤ê°€ ìš°ì—°íˆ ë¶€ì‹  ë©ì–´ë¦¬ë¥¼ ë°œê²¬í•œ ê²½ìš°.\n- **ì ‘ê·¼ë²•:**\n    - ê¸°ëŠ¥ì„ í•˜ëŠ”ê°€? (Hot/Functioning) -> ì¡°ì¹˜ í•„ìš”.\n    - ëª¨ì–‘ì´ í‰í•œê°€? (Ugly/Large) -> ì¡°ì¹˜ í•„ìš”.\n    - ì‘ê³  ê¸°ëŠ¥ì´ ì—†ë‹¤ë©´? -> ì§€ì¼œë³¸ë‹¤ (Watch).\n    - **ì£¼ì˜:** ë¶€ì‹  ì¢…ì–‘ì€ í•¨ë¶€ë¡œ **Biopsy í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.** (Pheoì¼ ê²½ìš° ë°”ëŠ˜ë¡œ ì°Œë¥´ë©´ Adrenal Crisis ìœ ë°œ ê°€ëŠ¥).\n---\n## 6. MEN Syndromes (Alphabet Soup) ğŸ§¬\nìœ ì „ì„± ë‚´ë¶„ë¹„ ì¢…ì–‘ ì¦í›„êµ°ì…ë‹ˆë‹¤. í—·ê°ˆë¦¬ê¸° ì‰¬ìš°ë‹ˆ íŒ¨í„´ì„ ì™¸ì›Œì•¼ í•©ë‹ˆë‹¤.\n### MEN 1 (The 3 P's)\n1. **P**ituitary adenoma (ë‡Œí•˜ìˆ˜ì²´ ì¢…ì–‘)\n2. **P**arathyroid hyperplasia (ë¶€ê°‘ìƒì„  ì¦ì‹ -> ê³ ì¹¼ìŠ˜í˜ˆì¦)\n3. **P**ancreas tumors (ì·Œì¥ ì¢…ì–‘)\n    - Gastrinoma (Zollinger-Ellison): ìœ„ì‚° ê³¼ë‹¤, ë‹¤ë°œì„± ê¶¤ì–‘.\n    - VIPoma: **W**atery **D**iarrhea, **H**ypokalemia, **A**chlorhydria (WDHA syndrome).\n### MEN 2 (The RET Proto-oncogene)\nMEN 2Aì™€ 2B ëª¨ë‘ **RET ìœ ì „ì ëŒì—°ë³€ì´**ì™€ ê´€ë ¨ ìˆìœ¼ë©°, ë‘ ê°€ì§€ ê³µí†µ ì¢…ì–‘ì„ ê°€ì§‘ë‹ˆë‹¤:\n- **ê³µí†µ:** **Medullary Thyroid Cancer (MTC)** & **Pheochromocytoma**.\n| **êµ¬ë¶„** | **MEN 2A** | **MEN 2B** |\n| --- | --- | --- |\n| **ì¶”ê°€ íŠ¹ì§•** | **Parathyroid Hyperplasia**\n (ë¶€ê°‘ìƒì„  ë¬¸ì œ -> ê³ ì¹¼ìŠ˜í˜ˆì¦) | **Mucosal Neuromas** (ì…ìˆ /í˜€ì— ë©ì–´ë¦¬)\n **Marfanoid Habitus** (í‚¤ í¬ê³  ë§ˆë¦„) |\n- **ì„ìƒ íŒ:** ì Šì€ í™˜ìê°€ ê°‘ìƒì„  ìˆ˜ì§ˆì•”(Medullary CA)ì´ë‚˜ ê°ˆìƒ‰ì„¸í¬ì¢…(Pheo)ì´ ìˆë‹¤ë©´ ë°˜ë“œì‹œ MEN ì¦í›„êµ°ì„ ì˜ì‹¬í•´ì•¼ í•©ë‹ˆë‹¤.\n---","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-229","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","diagnosis"]}
{"chunk_type":"recap_summary","text":"## ğŸ”¥ Rapid Fire Recap: High Yield Must-Knows\n1. **Thyroid Nodule Algorithm:** TSH ë¨¼ì €! **Low TSH = Hot Nodule = No Cancer = No Biopsy.**\n2. **Thyroglossal Duct Cyst:** ìˆ˜ìˆ  ì „ **ì •ìƒ ê°‘ìƒì„  ìœ„ì¹˜ í™•ì¸(Ultrasound/Scan)** í•„ìˆ˜. (ìœ ì¼í•œ ê°‘ìƒì„ ì¼ ìˆ˜ ìˆìŒ).\n3. **Hashimoto's Risk:** ì˜¤ë˜ëœ í•˜ì‹œëª¨í†  ê°‘ìƒì„ ì—¼ í™˜ìê°€ ê°‘ìê¸° ëª©ì´ ë¶“ê³  ë”±ë”±í•´ì§€ë©´ **Thyroid Lymphoma** ì˜ì‹¬. (**Pemberton Sign** ì²´í¬).\n4. **Thyroid Storm vs Malignant Hyperthermia:** ë‘˜ ë‹¤ ê³ ì—´/ë¹ˆë§¥ì´ì§€ë§Œ, **Rigidity(ê°•ì§)ê°€ ìˆìœ¼ë©´ MH**, ì—†ìœ¼ë©´ Storm.\n5. **Pheochromocytoma:** ë‘í†µ+ë°œí•œ+ë‘ê·¼ê±°ë¦¼(Triad). ì§„ë‹¨ì€ **Metanephrines** (not just catecholamines).\n6. **Neuroblastoma (Kids):** ë±ƒì† ë©ì–´ë¦¬ê°€ ì •ì¤‘ì„ ì„ ë„˜ìŒ(Crosses midline) + ì¶¤ì¶”ëŠ” ëˆˆ/ë°œ(Opsoclonus-myoclonus).\n7. **MEN 1:** 3 P's (Pituitary, Parathyroid, Pancreas).\n8. **MEN 2:** RET ìœ ì „ì. Medullary Thyroid CA + PheoëŠ” ê¸°ë³¸.\n    - 2AëŠ” Parathyroid (ì¹¼ìŠ˜ â†‘).\n    - 2BëŠ” Mucosal Neuroma + Marfanoid.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-249","focus_area":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","tags":["usmle-step2","core","recap","diagnosis","tree"]}
